PCSK9抑制剂在冠心病药物球囊术后患者中的应用
Application of PCSK9 Inhibitors in Patients with Coronary Heart Disease after Drug-Coated Balloon Therapy
摘要: 经皮冠状动脉介入治疗(PCI)技术的进步使药物涂层球囊(DCB)成为冠心病治疗的重要方式之一，尤其适用于支架内再狭窄、小血管病变及分叉病变等特定场景。然而，药物球囊术后患者仍面临动脉粥样硬化进展和血栓形成风险，需要强化降脂治疗。PCSK9i作为一类新型降脂药物，通过抑制前蛋白转化酶枯草溶菌素/kexin 9型(PCSK9)与低密度脂蛋白受体的结合，显著降低低密度脂蛋白胆固醇水平，并带来心血管获益。本文综述PCSK9i在冠心病药物球囊术后患者中的应用价值，包括其作用机制、临床证据、使用策略及未来展望，旨在为优化此类患者的血脂管理方案提供参考。
Abstract: The advancement of percutaneous coronary intervention (PCI) technology has established drug-coated balloons (DCB) as a significant approach in the treatment of coronary heart disease, particularly suited for specific scenarios such as in-stent restenosis, small vessel disease, and bifurcation lesions. However, patients after DCB treatment still face risks of atherosclerosis progression and thrombosis, necessitating intensive lipid-lowering therapy. As a novel class of lipid-lowering agents, PCSK9 inhibitors (PCSK9i) work by inhibiting the binding of proprotein convertase subtilisin/kexin type 9 (PCSK9) to the low-density lipoprotein receptor, significantly reducing low-density lipoprotein cholesterol levels and providing cardiovascular benefits. This article reviews the application value of PCSK9i in patients with coronary heart disease after DCB therapy, covering its mechanism of action, clinical evidence, usage strategies, and future prospects, aiming to offer references for optimizing lipid management in this patient population.
文章引用：蒋鹏, 陈国柱. PCSK9抑制剂在冠心病药物球囊术后患者中的应用[J]. 临床医学进展, 2026, 16(1): 2171-2177. https://doi.org/10.12677/acm.2026.161273

参考文献

[1] GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, Regional, and National Age-Sex Specific All-Cause and Cause-Specific Mortality for 240 Causes of Death, 1990-2013: A Systematic Analysis for the Global Burden of Disease Study 2013. The Lancet, 385, 117-171.
[2] Stock, J. (2015) Statin-Associated Muscle Symptoms EAS Consensus Panel Paper Focuses on This Neglected Patient Group. Atherosclerosis, 242, 346-350. [Google Scholar] [CrossRef] [PubMed]
[3] Bohula, E.A., Marston, N.A., Ruzza, A., Murphy, S.A., De Ferrari, G.M., Diaz, R., et al. (2024) Rationale and Design of the Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke (VESALIUS-CV) Trial. American Heart Journal, 269, 179-190. [Google Scholar] [CrossRef] [PubMed]
[4] Attie, A.D. and Seidah, N.G. (2005) Dual Regulation of the LDL Receptor—Some Clarity and New Questions. Cell Metabolism, 1, 290-292. [Google Scholar] [CrossRef] [PubMed]
[5] O’Donoghue, M.L., Giugliano, R.P., Wiviott, S.D., Atar, D., Keech, A., Kuder, J.F., et al. (2022) Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation, 146, 1109-1119. [Google Scholar] [CrossRef] [PubMed]
[6] Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., et al. (2015) Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 372, 1489-1499. [Google Scholar] [CrossRef] [PubMed]
[7] Huo, Y., Chen, B., Lian, Q., Wang, S., Liu, L., Lu, D., et al. (2023) Tafolecimab in Chinese Patients with Non-Familial Hypercholesterolemia (CREDIT-1): A 48-Week Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet Regional Health—Western Pacific, 41, Article 100907. [Google Scholar] [CrossRef] [PubMed]
[8] Kastelein, J.J.P., Nissen, S.E., Rader, D.J., Hovingh, G.K., Wang, M., Shen, T., et al. (2016) Safety and Efficacy of LY3015014, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): A Randomized, Placebo-Controlled Phase 2 Study. European Heart Journal, 37, 1360-1369. [Google Scholar] [CrossRef] [PubMed]
[9] Ray, K.K., Wright, R.S., Kallend, D., Koenig, W., Leiter, L.A., Raal, F.J., et al. (2020) Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine, 382, 1507-1519. [Google Scholar] [CrossRef] [PubMed]
[10] Johns, D.G., Campeau, L., Banka, P., Bautmans, A., Bueters, T., Bianchi, E., et al. (2023) Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation, 148, 144-158. [Google Scholar] [CrossRef] [PubMed]
[11] Ragusa, R., Rocchiccioli, S., Del Turco, S., Morlando, A., Basta, G., Scholte, A., et al. (2025) PCSK9 and Coronary Atherosclerosis Progression Beyond LDL-Cholesterol in Coronary Artery Disease Patients. European Journal of Clinical Investigation, 55, e70083. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, C., Zhou, T., Chen, Z., Yan, M., Li, B., Lv, H., et al. (2020) Coupling of Integrin Α5 to Annexin A2 by Flow Drives Endothelial Activation. Circulation Research, 127, 1074-1090. [Google Scholar] [CrossRef] [PubMed]
[13] Zhao, C.R., Yang, F.F., Cui, Q., et al. (2021) Vitexin Inhibits APEX1 to Counteract the Flow-Induced Endothelial Inflammation. Proceedings of the National Academy of Sciences, 118, e2115158118. [Google Scholar] [CrossRef] [PubMed]
[14] Zulkapli, R., Muid, S.A., Wang, S.M., Putera Mohd Yusof, M.Y. and Nawawi, H. (2025) Modulation of Atherogenesis Biomarkers by PCSK9 Inhibitors in Lp(a)-Stimulated Human Coronary Artery Endothelial Cells. BMC Cardiovascular Disorders, 25, Article No. 537. [Google Scholar] [CrossRef] [PubMed]
[15] Scheller, B., Speck, U., Abramjuk, C., Bernhardt, U., Böhm, M. and Nickenig, G. (2004) Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis. Circulation, 110, 810-814. [Google Scholar] [CrossRef] [PubMed]
[16] Cui, Y., Chen, Y., Li, H., Zhang, W., Wang, X., Xia, M., et al. (2025) PCSK9 Promotes Atherosclerotic Plaque Instability by Inducing VSMC Ferroptosis through the YAP1-NUPR1 Axis. Research, 8, Article 922. [Google Scholar] [CrossRef] 
[17] Nicholls, S.J., Kataoka, Y., Nissen, S.E., Prati, F., Windecker, S., Puri, R., et al. (2022) Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC: Cardiovascular Imaging, 15, 1308-1321. [Google Scholar] [CrossRef] [PubMed]
[18] Stepwise Dual Antiplatelet Therapy De-Escalation in Patients after Drug Coated Balloon Angioplasty (REC-CAGEFREE II): Multicentre, Randomised, Open Label, Assessor Blind, Non-Inferiority Trial. British Medical Journal, 389, r694.
[19] Akhtar, W., Khan, T., Neves, E., Browne, C., Tawil, M., Lyster, H., et al. (2025) PCSK9 Inhibitors in the Management of Hypercholesterolaemia after Heart Transplantation in the UK, a Single Centre Observational Study. Scientific Reports, 15, Article No. 35755. [Google Scholar] [CrossRef] 
[20] Huang, Y., Yang, A., Shi, M., Yu, J., Wu, H., Lui, J.N.M., et al. (2025) Trends of Lipid-Lowering Drug Utilization, Treatment Intensity and LDL-C Target Attainment in Adults with Diabetes and Non-Dialysis Chronic Kidney Disease in Hong Kong. The Lancet Regional Health—Western Pacific, 63, Article 101696. [Google Scholar] [CrossRef] 
[21] Gargiulo, P., Basile, C., Galasso, G., Bellino, M., D’Elia, D., Patti, G., et al. (2024) Strike Early-Strike Strong Lipid-Lowering Strategy with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Acute Coronary Syndrome Patients: Real-World Evidence from the AT-TARGET-IT Registry. European Journal of Preventive Cardiology, 31, 1806-1816. [Google Scholar] [CrossRef] [PubMed]
[22] Ren, J.Y., Zhang, H., Shao, X., Gu, T., Hu, S., Zhang, Y., et al. (2025) Impact of PCSK9 Inhibitors on Bleeding and Adverse Outcomes in Post-PCI Patients Undergoing Antiplatelet Therapy: A Real-World Cohort Study. International Journal of Cardiology, 434, Article 133352. [Google Scholar] [CrossRef] [PubMed]
[23] Ray, K.K., Colhoun, H.M., Szarek, M., Baccara-Dinet, M., Bhatt, D.L., Bittner, V.A., et al. (2019) Effects of Alirocumab on Cardiovascular and Metabolic Outcomes after Acute Coronary Syndrome in Patients with or without Diabetes: A Prespecified Analysis of the Odyssey Outcomes Randomised Controlled Trial. The Lancet Diabetes & Endocrinology, 7, 618-628. [Google Scholar] [CrossRef] [PubMed]
[24] Siasos, G., Oikonomou, E. and Tousoulis, D. (2020) Alirocumab and Evolocumab: An Indirect Comparison of Cardiovascular Benefits. European Heart Journal Cardiovascular Pharmacotherapy, 7, 236-237. [Google Scholar] [CrossRef] [PubMed]
[25] Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B.E., Camaj, A., Kalkman, D.N., et al. (2022) Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. European Heart Journal, 43, e17-e25. [Google Scholar] [CrossRef] [PubMed]
[26] Mach, F., Koskinas, K.C., Roeters van Lennep, J.E., Tokgözoğlu, L., Badimon, L., Baigent, C., et al. (2025) 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 46, 4359-4378. [Google Scholar] [CrossRef] 
[27] Niu, C., Parlapalli, A., Neenan, J., Ma, X., Osei-Wusu, A., Park, J., et al. (2023) Six-Month Adherence among Early Inclisiran Initiators vs. Anti-PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases. Circulation, 148.

为你推荐